Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Mar;35(2):443-57.
doi: 10.1093/schbul/sbn018. Epub 2008 Apr 15.

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

Christoph U Correll  1 , Christine Rummel-Kluge, Caroline Corves, John M Kane, Stefan Leucht
Affiliations
Meta-Analysis

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

Christoph U Correll et al. Schizophr Bull. 2009 Mar.

Abstract

Context: Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is common in schizophrenia.

Objective: To evaluate therapeutic and adverse effects of antipsychotic cotreatment vs monotherapy in schizophrenia.

Data sources: Cochrane Schizophrenia Group register and hand searches of relevant journals/conference proceedings.

Study selection: Randomized controlled trials comparing antipsychotic monotherapy to cotreatment with a second antipsychotic.

Data extraction and analysis: Two authors independently extracted data. For homogenous dichotomous data, we calculated random effects, relative risk (RR), 95% confidence intervals (CIs), and numbers needed to treat (NNT). For continuous data, weighted mean differences were calculated.

Results: In 19 studies (1229 patients) with 28 monotherapy and 19 cotreatment arms, antipsychotic cotreatment was superior to monotherapy regarding 2 a priori defined coprimary outcomes: less study-specific defined inefficacy (N = 22, n = 1202, RR = 0.76, CI = 0.63-0.90, P = .002, NNT = 7, CI = 4-17, P = .0008, I(2) = 78.9%) and all-cause discontinuation (N = 20, n = 1052, RR = 0.65, CI = 0.54-0.78, P < .00001). Results were consistent using Clinical Global Impressions thresholds of less than much (P = .006) and less than minimally (P = .01) improved. Specific psychopathology and adverse event data were insufficient to yield meaningful results. In sensitivity analyses, 5 efficacy moderators emerged: concurrent polypharmacy initiation, clozapine combinations, trial duration >10 weeks, Chinese trials, and second-generation + first-generation antipsychotics. In a meta-regression, similar dose combinations, second-generation + first-generation antipsychotics and concurrent polypharmacy initiation remained significant.

Conclusions: In certain clinical situations, antipsychotic cotreatment may be superior to monotherapy. However, the database is subject to possible publication bias and too heterogeneous to derive firm clinical recommendations, underscoring the need for future research.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Included and Excluded Studies With Reasons: The Quality of Reports of Meta-analysis (QUOROM) Flow Diagram.
Fig. 2.
Fig. 2.
Lack of Efficacy as Defined in Each Study.
Fig. 3.
Fig. 3.
Leaving the Study Early for any Reason.
Fig. 4.
Fig. 4.
Funnel Plot of Symmetry of Published Results.
See this image and copyright information in PMC

References

    1. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–1416. - PubMed
    1. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry. 2006;63(10):1079–1087. - PubMed
    1. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005;353(12):1209–1223. - PubMed
    1. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–479. - PubMed
    1. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 1988;24(1):62–67. - PubMed

Publication types